Core Viewpoint - Heng Rui Medicine (600276) (01276) experienced a rise of over 5%, currently up 5.61% at HKD 74.3, with a trading volume of HKD 126 million [1] Group 1: Clinical Trial Approvals - On November 25, Heng Rui Medicine announced the receipt of clinical trial approval notices from the National Medical Products Administration for two drugs [1] - The HRS-8364 tablets will soon commence clinical trials for advanced solid tumors, with no similar drugs approved for market domestically or internationally [1] - Cumulative R&D investment for the HRS-8364 project is approximately RMB 21.65 million [1] Group 2: Additional Drug Development - The injectable Rukang Trastuzumab will also begin clinical trials for patients with HER2-positive solid tumors [1] - Cumulative R&D investment for the injectable Rukang Trastuzumab project is around RMB 1.41 billion [1]

Core Viewpoint - Heng Rui Medicine (01276) experienced a stock price increase of over 5%, currently up 5.61% at HKD 74.3, with a trading volume of HKD 126 million [1] Group 1: Clinical Trial Approvals - On November 25, Heng Rui Medicine announced the approval from the National Medical Products Administration for two drug clinical trial notifications [1] - The HRS-8364 tablet will soon commence clinical trials for advanced solid tumors, with no similar drugs approved for market domestically or internationally [1] - Cumulative R&D investment for the HRS-8364 project is approximately RMB 21.65 million [1] Group 2: Additional Drug Development - The injectable Rukang Trastuzumab will also begin clinical trials for patients with HER2-positive solid tumors [1] - Cumulative R&D investment for the injectable Rukang Trastuzumab project is around RMB 1.41 billion [1]

Group 1: National Policies and Initiatives - The National Space Administration has issued a plan to promote high-quality and safe development of commercial aerospace from 2025 to 2027, encouraging the strengthening of satellite and rocket manufacturing, expanding application services, and enhancing measurement and control operations [1] - The National Data Bureau supports the establishment of a comprehensive service system for data trading, emphasizing the role of data exchanges in product incubation, compliance assurance, and market integration [2] - The Ministry of Science and Technology aims to implement major national scientific tasks to achieve breakthroughs in key technologies, enhancing collaboration between enterprises and research institutions [5] Group 2: Corporate Developments - Moore Threads announced the results of its initial public offering, with a total of 33,600 winning numbers for subscriptions, allowing each winning number to subscribe for 500 shares [4] - Huayou Cobalt signed a supply agreement with Yiwei Lithium Energy for high-nickel ternary cathode materials, expected to supply approximately 127,800 tons from 2026 to 2035, enhancing its market share in lithium battery materials [5] - Shangwei New Materials elected Peng Zhihui as chairman and appointed Tian Hua as CEO during its board meeting [6][7] - Shida Group is advancing its investments in intelligent computing, leveraging policy advantages from digital initiatives in Fujian [7] - Heng Rui Medicine received approval for clinical trials of its innovative drug HRS-8364 for treating advanced solid tumors, with no similar drugs approved in the market [8] - Spring Autumn Electronics plans to acquire all shares of Asetek A/S for up to 573 million Danish Krone, focusing on liquid cooling technology for PCs [9] - Tianfu Communication's major shareholder transferred 3.011 million shares for 422 million yuan, with no impact on the company's control structure [10] - Century Huatong obtained a loan commitment of up to 900 million yuan from China Merchants Bank for stock repurchase [11] - Demingli plans to raise up to 3.2 billion yuan for expanding SSD and DRAM production projects [12] - Dayang Electric is investing 10 million yuan in an industrial fund focused on robotics and related technologies [13] - Guosheng Technology intends to acquire 100% of Fuyue Technology for 240.6 million yuan, which specializes in high-precision lithium battery components [13]

11月26日，恒瑞医药盘中上涨2.14%，截至09:49，报62.18元/股，成交5.87亿元，换手率0.15%，总市值 4127.01亿元。 资金流向方面，主力资金净流入7527.32万元，特大单买入8020.23万元，占比13.65%，卖出2830.32万 元，占比4.82%；大单买入1.41亿元，占比24.08%，卖出1.18亿元，占比20.10%。 恒瑞医药今年以来股价涨36.06%，近5个交易日涨1.75%，近20日跌2.87%，近60日跌4.78%。 资料显示，江苏恒瑞医药股份有限公司位于江苏连云港市经济技术开发区昆仑山路7号,中国香港铜锣湾 希慎道33号利园1期19楼1920室，成立日期1997年4月28日，上市日期2000年10月18日，公司主营业务涉 及江苏恒瑞医药股份有限公司是一家主要从事药品的研发、生产和销售的中国公司。该公司专注于肿瘤 领域，覆盖激酶抑制剂、抗体偶联药物（ADC）、肿瘤免疫、激素受体调控、脱氧核糖核酸（DNA） 修复及表观遗传、支持治疗等研究领域。该公司的产品包括抗肿瘤、镇痛麻醉和造影剂，应用于自身免 疫疾病、代谢性疾病、心血管疾病、感染疾病、呼吸系统疾病、血液疾病、疼 ...

Industry News - The National Space Administration has issued an action plan for promoting high-quality and safe development of commercial aerospace from 2025 to 2027, which includes the establishment of a national commercial aerospace development fund to encourage long-term, strategic, and value investments by local governments, financial institutions, and social capital [3] - The State Taxation Administration reported that from January to October 2025, tax authorities have investigated 3,904 high-risk gas stations, recovering tax and penalties totaling 3.644 billion yuan, in collaboration with public security, commerce, and market regulation departments to promote fair competition in the market [3] - The National Bureau of Statistics announced plans to promote state-owned enterprises to break down data barriers and actively open data resources for efficient and secure cross-enterprise and cross-industry data flow [3] - The Cyberspace Administration has recently cracked down on several illegal mobile internet applications that failed to implement regulations on labeling AI-generated content, taking measures such as interviews, deadlines for corrections, and removals [3] Company News - Tianfu Communication announced that its controlling shareholder, Tianfu Renhe, transferred 3.011 million shares for a total amount of 422 million yuan [6] - Alibaba Group reported its Q2 FY2026 earnings, with revenue of 247.8 billion yuan, a year-on-year increase of 4.8%, and adjusted net profit of 10.35 billion yuan. The Cloud Intelligence Group's revenue reached 39.82 billion yuan, up 34% year-on-year [6] - Shannon Semiconductor announced that its directors and executives plan to reduce their holdings by no more than 270,000 shares [7] - Upwind New Materials announced the election of Peng Zhihui as chairman and the appointment of Tian Hua as CEO [8] - Century Huatong announced that it has obtained a commitment letter for a stock repurchase special loan from China Merchants Bank of no more than 900 million yuan [9] - Heng Rui Pharmaceutical announced that its innovative drug HRS-8364 for the treatment of advanced solid tumors has received clinical trial approval, with no similar drugs approved for market in China and abroad [9] - Fusenmei announced that its deputy general manager and board secretary, Zhang Fengshu, is under investigation and has been placed under detention [10] - NIO released its Q3 2025 earnings report, with revenue of 21.79 billion yuan, a year-on-year increase of 16.7% and a quarter-on-quarter increase of 14.7%. The revenue guidance for Q4 indicates a year-on-year growth of 66% to 73%, reaching a historical high [10] - Guosheng Technology announced plans to acquire 100% equity of Fuyue Technology for 240.6 million yuan, with the target company primarily engaged in the research, production, and sales of high-precision new lithium battery components [10] - Huayou Cobalt announced a supply agreement for ultra-high nickel ternary cathode materials with Yiwei Lithium Energy, aiming to enhance its market share in lithium battery new energy materials [10] - Demingli announced plans to raise no more than 3.2 billion yuan for solid-state drives and memory product expansion projects [11] - Dayang Electric announced an investment of 10 million yuan to participate in an industrial fund, focusing on products related to embodied robots and mechanical arms [12] - Junting Hotel announced that its controlling shareholder is planning a change in company control, leading to a stock suspension [13] - Yidian Tianxia announced that its second-largest shareholder, Ningbo Zhongdianyi, has cumulatively reduced its holdings by 13.9712 million shares from October 28 to November 25 [14]

新华财经上海11月25日电 （谷青竹）2025年以来，中国创新药出海在政策红利与产业积累的双重驱动下，呈现"规模与质量同步跃升"的态势。初步统计显 示，到10月末的对外授权（License-Out）总金额已超900亿美元，较2024年全年的519亿美元近乎翻倍，大额合作与标杆企业业绩持续刷新行业纪录。这场出 海热潮不仅是中国创新药全球化布局"狂飙突进"的缩影，同时也暴露出一些行业短板需持续破解。 提质增速：三季度出海"含金量"创新高 进入下半年，中国创新药出海延续增长势头，不仅交易规模和结构显著优化，商业化能力也取得实质性突破，"含金量"明显提升。 据介绍，恒瑞医药与葛兰素史克（GSK）的合作是近期行业标志性事件之一。据介绍，双方于7月达成覆盖呼吸、自身免疫及肿瘤三大领域的全球战略合 作，涉及12款创新药，恒瑞获得5亿美元首付款、潜在里程碑付款高达120亿美元。尤为关键的是，恒瑞在协议中保留了"联合商业化选择权"，得以深度参与 全球收益分配，标志着中国药企正从传统的"授权许可方"向具备全球商业化话语权的"协同开发者"转变。 印证国际药企对中国源头创新的高度认可，并不只这一个案例。更早前的5月，三生制药将其自主 ...

今日聚焦 1、摩尔线程中签号出炉 共有33600个 摩尔线程发布首次公开发行股票并在科创板上市网下初步配售结果及网上中签结果公告，本次发行战略配售的缴款及配售工作已结束，本次发行最终战略 配售结果如下。中签号码共有33600个，每个中签号码只能认购500股摩尔线程A股股票，中签结果如下。 | 末尾位数 | 中签号码 | | --- | --- | | 末"4"位数 | 5878, 0878, 9856 | | 末"5"位数 | 82351, 62351, 42351, 22351, 02351, 01433 | | 末"6"位数 | 531423, 031423, 735823 | | 末"7"位数 | 7314483, 9814483, 4814483, 2314483 | | 末"8"位数 | 50424341, 12313399, 54014918, 63005163, 88007204, | | | 17371775, 27066860, 12908735, 58145735 | 2、华友钴业：与亿纬锂能签订超高镍三元正极材料供应协议 提升公司锂电新能源材料市场占有率 华友钴业(603799.SH)公 ...

注射用瑞康曲妥珠单抗可通过与HER2表达的肿瘤细胞结合并内吞，在肿瘤细胞溶酶体内通过蛋白酶剪 切释放毒素，诱导细胞周期阻滞从而触发肿瘤细胞凋亡。其释放的毒素具有高透膜性，可发挥旁观者杀 伤效应，进一步提高抗肿瘤疗效。经查询，目前国外已上市的同类产品有罗氏公司研发的Ado- trastuzumab emtansine及阿斯利康与第一三共合作研发的Fam-trastuzumab deruxtecan，且均已在国内上 市。除此之外，荣昌生物研发的维迪西妥单抗于2021年在国内获批上市，科伦博泰研发的博度曲妥珠单 抗于2025年在国内获批上市。经查询EvaluatePharma数据库，2024年以上同类产品全球销售额合计约为 65.57亿美元。截至目前，注射用瑞康曲妥珠单抗相关项目累计研发投入约141,475万元。 公司注射用瑞康曲妥珠单抗已于2025年5月在国内获批上市，适用于治疗存在HER2(ERBB2)激活突变且 既往接受过至少一种系统治疗的不可切除的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者。 恒瑞医药（600276）(01276)发布公告，近日，公司子公司苏州盛迪亚生物医药有限公司收到国家药监 局核 ...

Core Insights - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of injection-based Rukang Qutuzumab [1] - The drug is set to be launched in China in May 2025, targeting adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) who have HER2 (ERBB2) activating mutations and have previously received at least one systemic treatment [1] Group 1 - Rukang Qutuzumab works by binding to HER2-expressing tumor cells, leading to internalization and release of toxins in the tumor cell lysosome, which induces cell cycle arrest and triggers tumor cell apoptosis [2] - The released toxins exhibit high membrane permeability and can exert bystander killing effects, enhancing anti-tumor efficacy [2] - Similar products already on the market include Roche's Ado-trastuzumab emtansine and AstraZeneca's Fam-trastuzumab deruxtecan, both of which have been launched in China [2] Group 2 - The global sales of similar products are projected to reach approximately $6.557 billion from 2024 onwards [2] - The cumulative R&D investment for Rukang Qutuzumab has reached approximately 141.475 million yuan [2]

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of HRS-8364 tablets, an innovative anti-tumor drug developed by the company, aimed at treating advanced solid tumors [1] Group 1: Product Development - HRS-8364 tablets are a self-developed innovative anti-tumor drug [1] - The drug is intended for the treatment of advanced solid tumors [1] - Currently, there are no similar drugs approved for sale in both domestic and international markets [1] Group 2: Financial Investment - The total research and development investment for the HRS-8364 project has reached approximately 21.65 million yuan [1]